Skip to main content
Terug
ELVN logo

Enliven Therapeutics, Inc.

Datakwaliteit: 100%
ELVN
NASDAQ Healthcare Biotechnology
€ 31,15
▲ € 0,34 (1,10%)
Marktkapitalisatie: 1,86B
Dagbereik
€ 29,44 € 31,32
52-Weeksbereik
€ 13,30 € 31,76
Volume
1.010.285
50D / 200D Gem.
€ 27,54 / € 21,92
Vorige Slotkoers
€ 30,81

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -18,0 0,3
P/B 4,1 2,9
ROE % -27,0 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 43,33 +39.1%
Low: € 39,00 High: € 52,00
Forward WPA
-€ 2,12
Omzet Sch.
10000

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 -€ 1,90
-€ 1,90 – -€ 1,90
210 M 1
FY2029 -€ 3,47
-€ 3,47 – -€ 3,47
41 M 1
FY2028 -€ 3,81
-€ 5,11 – -€ 1,93
25000 5

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -70,46M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-26,95%
ROIC-19,51%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio28,66
Interest Coverage0,00

Waardering

P/E Ratio
-17,96
P/B Ratio4,05
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -103,69M
ROE -26,95% ROA -21,78%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -70,46M
ROIC -19,51% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 28,66
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -17,96 P/B Ratio 4,05
P/S Ratio N/A PEG Ratio 2,65
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,86B Enterprise Value 1,76B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -103,69M -89,02M -71,58M -37,66M -24,74M
EPS (Diluted) -1,83 -1,89 -2,01 -6,03 -3,17
Gross Profit -263.000,0 0,0 0,0 0,0 0,0
Operating Income -119,66M -104,55M -83,53M -38,79M -24,76M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 476,17M 325,76M 271,87M 83,30M 113,33M
Total Liabilities 16,68M 15,92M 25,96M 160,12M 6,47M
Shareholders' Equity 459,60M 309,85M 245,91M -76,83M 106,86M
Total Debt 399.000,0 0,0 335.000,0 323.000,0 159.000,0
Cash & Equivalents 98,90M 124,12M 100,14M 75,54M 110,02M
Current Assets 474,88M 318,13M 266,15M 77,75M 110,67M
Current Liabilities 16,57M 15,92M 25,89M 9,72M 5,75M